Back to News
Market Impact: 0.2
Mizuho Initiates Coverage of REGENXBIO at Outperform
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Mizuho initiated coverage of REGENXBIO on October 5, 2026, with an Outperform recommendation. The article provides no price target, financial estimates, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
RGNX0.50
More News
- JPMorgan and Deutsche Bank just upgraded Brazilian stocks. How to trade them
- GIC Private Ltd, Medline 10% owner, sells over $721m in shares
- Meta may ditch the idea of a cloud business for Muse. We think that’s a good trade
- Why is Broadcom stock rallying today?
- Why is Telix Pharmaceuticals stock rallying today?
- A new analyst call on Home Depot reflects our feeling on what to do with the stock
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- The Great Divergence: North American Banking at the Crossroads of Monetary Policy and Agentic AI (Q4 2025 Bank Earnings)
- AI for M&A Target Screening: From Universe to Deal File